Angiodynamics reports fiscal 2022 third quarter financial results; reaffirms fiscal year 2022 guidance

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2022, which ended february 28, 2022. “we are proud of our team's ability to drive continued growth in our business during the third quarter while operating
ANGO Ratings Summary
ANGO Quant Ranking